Acid trip ends pandemic: issue 38

Hello and welcome back.

After two years of Covid ruling our lives, it seems like we can finally see the light at the end of the tunnel. That might not be the case if it weren’t for psychedelics. Keep reading to discover how LSD lead to the invention of a tool that’s been essential for detecting Covid! 

Here’s what’s in store for you in today’s issue:

🍄 What a DMT trip actually feels like

🍄 The legal psychedelic that’s replacing alcohol

🍄 World’s first DMT trial for depression

🍄 How psychedelics could treat eye disease 👀

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Michael Kydd opens up about the impact of losing his mother at a young age

On this episode of the Daily Mushroom Podcast, we have Michael Kydd, an independent consultant helping psychedelic companies navigate the complex world of government relations. in this emotional episode, Michael talks about his experience with the passing of his mother, and how he believes psychedelics could have strongly benefited his mothers and his family in that difficult time. 

Therapeutic banner

World’s first DMT trial for depression

Small Pharma (DMT) successfully completed a phase I trial on the safety of DMT in preparation for a phase II trial on depression. Researchers discovered that:

  • Most of the 24 patients described the experience as pleasurable and not too challenging (even though no one had tried psychedelics before)
  • Although there were 20 adverse events (85% mild, 15% moderate, and 0% severe), no patient regretted participating
  • The trip lasted 20 minutes, and DMT was nearly undetectable in the blood after 60 minutes
  • For three months following the dose, there were no significant negative effects on anxiety or well-being

Phase II results are expected in the first half of this year, which will reveal how one dose compares to two doses in treating depression.

Discovering self-worth with ketamine

Despite having a supportive family and a healthy lifestyle, Sarah had crippling self doubt and suicidal ideation. It wasn’t until she tried ketamine therapy that she realized why she felt these emotions.

The experience revealed that she never healed the scars of feeling unloved during her parents’ divorce. Her dream-like visions on ketamine showed her that separation is a natural part of life, and that she doesn’t need to be perfect to deserve love.

Sarah finally believes “I’m worth being here,’ she says. 

How psychedelics treat eye disease

Glaucoma can cause irreversible vision loss and blindness. Current medications require multiple daily applications and have side effects like redness and stinging of the eyes.

PharmaDrug (PHRX) wants to develop a superior treatment using analogues of DMT.

The company discovered that the compounds can “activate protective pathways within critical cellular compartments of the eye” to reduce pressure inside the eye. 

PharmaDrug will collaborate with the Terasaki Institute for Biomedical Innovation (TIBI) to produce a device that can deliver low doses of the drug to the front of the eye. 

inspirational banner

What a DMT trip actually feels like

Researchers interviewed 36 people immediately after a DMT trip. Here’s what they discovered:

  • All 36 people reported “entering other worlds”
  • 94% encountered some sort of otherworldly being or entity 
  • Entity encounters were overwhelmingly positive and often provided personal and cosmic insights (like self love or the game-like nature of reality)
  • 81% described the trip as “hyperreal” 

DMT increases theta brain waves, which are associated with dreaming, but it’s unclear why people have such similar “dreams” 🤔

Acid-inspired invention earns Nobel Prize

LSD led to the invention of a technology that has slowed the spread of Covid and even earned a Nobel Prize – the PCR test.

Chemist Kary Mullis experimented with lots of synthetic psychedelics, which is no surprise considering he was friends with Albert Hofmann, the creator of LSD. 

He believes psychedelics made him think more creatively and gave him visions of sitting on DNA molecules. When asked if he would have invented PCR technology without LSD, he responded, “I doubt it. I seriously doubt it.”

So this pandemic would likely be a lot longer if it weren’t for LSD!

Replace alcohol with this legal psychedelic drink

Psychedelic Water is a mildly psychoactive drink made with kava root, a herb used by Pacific Islanders in ceremonies for relaxation. The mood-boosting effect makes it the ideal replacement for alcohol. 

Psychedelic Water is having a buy one get one free sale to celebrate the launch of a new flavour – Prickly Pear!

Even multi-platinum producer Murda Beatz is a fan. “I want something that will make me feel good & expand my creativity; Psychedelic Water does exactly that,” he says.

business banner

COMPASS Pathways (CMPS) reported 2021 financial result including a net loss of  $71.7 million ($1.79 loss per share) and $273.2M in cash. The company had a $60.3M loss ($3.55 loss per share) and $190.3M in cash in 2020.

Optimi Health (OPTI) and Doseology Sciences (MOOD) both launched functional mushroom product lines in Canada. The global market for functional mushrooms is expected to grow at a 7.23% compound annual growth rate through 2027.

Filament Health (FH) will license its natural psilocybin to ATMA Journey Centers for use in clinical trials, including an upcoming phase I trial on healthy subjects, which has already received Health Canada approval.

Biomind Labs (BMND), a company researching DMT, 5-MeO-DMT, and mescaline, began trading on the OTCQB market under the symbol “CRSWF” and received DTC eligibility in the US.

legal banner

Help patients and clinicians fight for their right to psilocybin

Our friends at TheraPsil helped 86 clinicians apply for Section 56 exemptions so they could participate in a psilocybin therapy training program.

Unfortunately, Health Canada denied the clinicians access to psilocybin, which will impact over 1500 patients who are desperately awaiting psilocybin treatments. Many Canadians will die before they have the chance to try psilocybin therapy.

TheraPsil needs our help to raise $100K to take the Canadian government to court to achieve lasting policy change so that Canadians can access the treatment before it’s too late. 

Plus:

  • The DEA proposed adding 5 more psychedelics to the list of Schedule I substances, which would impede research on the substances. After receiving pushback from the research community, the DEA’s administrative court agreed to hold hearings on the issue. Read more…
  • A bill to form a psychedelic research task force was passed by a Utah Senate committee after passing in the House. The task force will advise regulations surrounding dosage, training, licensing, and safety requirements if therapeutic use is legalized. Read more..
  • Senate committee in Oregon unanimously approved a bill to create a psilocybin equity task force that will guide the state’s psilocybin therapy program. Read more…

Video of the Week

Playlist of the Week

Biomind Labs Announces DTC Eligibility in the United States

Biomind Labs Announces DTC Eligibility in the United States

TORONTO–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce that it has received confirmation from the Depository Trust Company (the “DTC“) that its common shares are now eligible for electronic clearing and settlement through the DTC in the United States.

Alejandro Antalich, Chief Executive Officer and Director of Biomind Labs, said: “We are pleased to have obtained our DTC eligibility, complementing our recent listing approval on the OTCQB Venture Market announced on February 17, 2022. This eligibility will simplify the process of trading shares in the United States, which will be beneficial to Biomind Labs and our shareholders. With DTC eligibility, the increased accessibility and visibility is expected to attract greater investment and trading liquidity from American investors as our shares will be available to a broader range of investors. We look forward to inviting existing and prospective investors to be a part of Biomind Labs’ ambition to continue to grow and facilitate the future generation of pharmaceuticals.”

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of securities for publicly traded companies in the United States. With DTC eligibility, existing investors and brokers benefit from potentially greater liquidity, execution speeds, and reduction in costs, while opening the door to new investors that may have been previously restricted from the Company’s common shares.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking statements in this document include, among others, statements relating to the ability of the Company’s innovation and research on endogenous tryptamines to possibly treat mental health disorders and beyond, the Company’s DTC eligibility possibly resulting in increased accessibility, visibility and attracting greater investment and trading liquidity from American investors, the Company’s novel pharmaceutical formulations treating a wide range of therapeutic indications and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Shroom use →  less crime

Psilocybin use associated with lowered odds of having been arrested, study finds

People who use shrooms are less likely to commit crimes, according to new research.

An analysis of The National Survey on Drug Use and Health found that psilocybin use is linked to significantly reduced odds of arrest for:

  • Larceny
  • Burglary & robbery
  • Simple assault & battery
  • Serious violence
  • DUI
  • And other miscellaneous crimes

LSD appeared to have no impact on crime rates 🤔

PDF of article

Biomind Labs to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Biomind Labs to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

TORONTO, December 02, 2021–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (FSE: 3XI), a leading biotech company in fast-acting psychedelics is pleased to announce that Alejandro Antalich, Chief Executive Officer, and Dr. Draulio Barros de Araujo, Scientific and Clinical Advisor, will participate at the 2nd Annual H.C. Wainwright Psychedelics Conference being held virtually on Monday, December 6, 2021.

“The title of the Conference: “Back to the Future: Positioning for the Psychedelic Comeback in Mental Healthcare and Beyond“, aligns to the pharmaceutical drug development strategy of Biomind, that goes beyond mental health conditions, targeting conditions such as Fibromyalgia, Chronic Pain and Inflammation Disorders, as well. It is a great opportunity to get a comprehensive understanding of the diversified portfolio of molecules targeting specific indications and tailored drug delivery systems, as well as the robust intellectual property strategy, of Biomind.

Biomind Labs’ conference will be available on demand beginning on December 6, 2021, at 7:00 a.m. ET. To access to the conference, click here, please enter “Presenting Company”, then a form will be enabled to complete. The archived webcast will also be available on the Company’s investor relations website.

About Biomind Labs Inc.
Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-Dimethyltryptamine (“DMT”), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments and use cases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking statements in this document include, among others, statements relating to expectations and the potential benefits of the Company’s clinical research, the Company’s robust intellectual property strategy, the business plans and growth plans of the Company and other statements that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptaminebased treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005432/en/

Contacts

Biomind Labs Inc.
Alejandro Antalich
Chief Executive Officer
Email: alejandro.antalich@biomindlabs.com

Win + Support + Microdose + Covid-19 🍄: issue 25

Here’s what’s in store for you in today’s issue:

🍄 Results from a global microdosing study

🍄  Ayahuasca vs. placebo

🍄 3D-printed psychedelics

🍄 Can mushrooms fight covid?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Where Religion And Psychedelics Collide

In this episode of the Daily Mushroom Podcast, we have Peg Peters. Peg is setting up a ketamine-assisted psychotherapy clinic just outside of Vancouver, BC. He discovered psychedelics in his mid 40s, taking a 6g dose of psilocybin mushrooms while accompanied by a therapist. After that experience his career in psychedelics took off!

Therapeutic banner

Ayahuasca vs placebo

An ayahuasca retreat could make you more empathetic!

In a recent study, participants reported reduced stress, anxiety, and depression after attending an ayahuasca ceremony… even those who were given a placebo. 

However, only the ayahuasca users showed increased empathy.

The supportive group atmosphere could explain why people experienced benefits even without taking ayahuasca. 

Don’t get triggered

Researchers discovered that DOI (a psychedelic that’s similar to LSD and mescaline) can reduce anxiety and increase neural plasticity. Rats stopped showing anxious behaviours in response to fear triggers after a single dose!

How psychedelic ceremonies change your beliefs

A survey of ~900 psychedelic ceremony attendees revealed that psychedelic use is associated with a decreased belief in materialism, an increase in transcendentalism, and improved mental health. Participants showed more moderate views on metaphysical beliefs after the ceremony rather than extreme stances.

inspirational banner

GIVEAWAY ALERT 🚨

You could win $4,000+ in prizes for supporting legal access to psychedelics!

By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.

If that’s not enough, you’ll also be entered to win an incredible prize package including:

  • A scholarship towards a Holos Plant Medicine retreat (Value: $1,500)
  • A 2-night stay at the Sentinel Retreat Centre (Value: $500)
  • A functional mushroom wellness package from Eversio Wellness (Value: $300)
  • 1 of 3 Physiology of Trauma premium masterclass packages from Nectara (Value: $900)
  • And more!

Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.

Purchase a membership before December 10th to be entered in the giveaway!

Get ready for a psychedelic TV series coming this summer!

This month’s issue of Los Angeles Magazine features an in-depth cover story on the city’s recent obsession with psychedelics. 

Now, the story is being developed into a drama/comedy series called Psychedelic City (think Silicon Valley meets Limitless).

The writer hopes the show will “wipe away some of the stigmas that have been attached to psychedelics.”

The developers are also creating a Psychedelic City metaverse platform with immersive art, music, and experimental therapies. 

business banner

Biomind Labs (BMND) developed a new way to manufacture psychedelics using 3D printers and lasers. By printing the formulation layer by layer, the company can control exactly when the drug is released and adjust doses for each patient.

LOVE Pharma (LUV) signed a letter of intent to acquire Microdoz Therapy Inc. to accelerate a psilocybin trial for cannabis use disorder. Seems ironic considering that the company also sells THC and CBD oral strips!

Entheon Biomedical (ENBI) has begun testing the stability of its DMT formulation in preparation for a study on nicotine addiction.

PharmaTher (PHRM) applied for an orphan drug designation for a ketamine treatment for a rare seizure condition called Status Epilepticus. If approved, the designation would give the company potential tax credits, grant eligibility, and exclusive marketing rights.

Pasithea Therapeutics (KTTA) began offering an esketamine nasal spray at its UK clinics. It’s one of just three clinics in the UK that have been approved to provide the treatment.

MYND Life Sciences (MYND) began research on its biomarker test that aids in diagnosing multiple sclerosis. There are currently no physical indicators or lab tests that can diagnose the condition.

Researchers are turning to fungi to treat covid!

In an upcoming clinical trial, agarikon and turkey tail mushrooms will be given to covid-positive patients with mild symptoms. Researchers hope that the mushrooms’ antiviral and immune-boosting properties will prevent symptoms from worsening.

In a separate trial, the same blend of mushrooms will be given to subjects while getting vaccinated to see if it can boost antibody levels.

Industry Quick Hits

Nov 22 – Emyria Ltd (EMD) receives $5 million from one of Australia’s largest private investment groups Read more…

Nov 23 – Cybin (CYBN) Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities Read more…

Nov 23 – COMPASS Pathways (CMPS) granted fifth US patent for crystalline psilocybin Read more…

Nov 24 – Seelos Therapeutics (SEEL) Acquires Exclusive License of iX Biopharma’s Proprietary Wafer-Based Ketamine Delivery Platform Read more…

Nov 24 – NeonMind (NEON) Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001  Read more…

Nov 26 – Numinus (NUMI) Receives Conditional Approval to Graduate to the Toronto Stock Exchange Read more…

Video of the Week

Playlist of the Week

Biomind Labs to Advance a Phase II Clinical Trial on DMT for Treatment-Resistant Depression

TORONTO — Biomind Labs Inc. (“Biomind Labs” or the “Company”) ( NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that its Phase II clinical trial on N, N-dimethyltryptamine (“DMT”) for treatment-resistant depression has been approved by the Brazilian Institutional Review Board.

“A paramount step in our rapid evolution that positions us at the forefront of clinical research on the DMT molecule. DMT is an indole alkaloid found endogenously in various plant species and in humans, it is found primarily in the lungs, thyroid, adrenal gland, and in lower concentration in the brain. DMT provides the principal psychedelic in the Amazonian decoction, ayahuasca. According to a recent randomized placebo-controlled trial in patients with treatment-resistant depression conducted by our Neuroscientist Dr. Draulio Barros de Araujo, published in Psychological Medicine, ayahuasca is safe and presented a rapid antidepressant effect. This clinical trial is the first and the only completed randomized placebo-controlled trial to test a psychedelic substance in treatment-resistant depression. The results of this trial were crucial for Biomind Labs to be able to advance with an isolated form of DMT”, said Alejandro Antalich, CEO of Biomind Labs.

Article content

The Phase II clinical trial will be conducted by Dr. Draulio Barros de Araujo, will include 40 individuals and will be conducted in Brazil. Given the safety profile, the absence of overdose, tolerance and previous results with ayahuasca, Biomind Labs continues to reinforce the Molecule Clinical Development Dossier of its novel pharmaceutical BMND01, enabling a potentially successful molecule-to-market lifecycle.

“Approximately 20-30% of people with depression have inadequate responses to antidepressants and psychotherapies, even after multiple interventions. Treatment-resistant depression places great demands on healthcare resources and on patients, many of whom attempt and die by suicide. This scenario makes the search for new treatments a necessity. Clinical trials carried out in recent years have shown rapid antidepressant responses to psychedelic substances. Our scientific team is a pioneer in conducting clinical trials, using open and randomized designs with psychedelic substances in patients with treatment-resistant depression”, commented Dr. Draulio Barros de Araujo.

“We believe that DMT possesses a number of benefits in comparison to other tryptamine compounds such as psilocybin. This includes a short psychedelic experience with a duration of less than 30 minutes compared to other psychedelic compounds, including psilocybin, whose duration of experience typically lasts six hours, LSD typically lasts ten hours and ayahuasca four hours. The significant reduction in experience duration provides greater practical applicability to potentially deliver the psychedelic treatment in a supervised real-world clinical setting. This is also highly relevant to affordability, one of our core objectives. While establishing a close relationship with the psychiatry community, government authorities and health agencies, we are working towards a potentially massive and affordable solution for millions of patients suffering from depression, anxiety and eating disorders, among others”, concluded Antalich.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main natural psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to guarantee patients access to affordable and modern-day treatments and use cases. Biomind Labs understands that long-lasting psychedelic effects make it difficult to create adequate clinical protocols to serve a larger number of patients, and this is the reason why Biomind Labs specializes in fast-acting psychedelics.

Article content

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking statements in this document include, among others, statements relating to expectations regarding the results and timelines of the Company’s Phase II clinical trial, the molecule-to-market lifecycle of BMND01, the potential health benefits of DMT, building strong relationships with the psychiatric community, government authorities and health agencies, the business plans and growth plans of the Company and other statements that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

Article content

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005361/en/

Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application

TORONTO — Biomind Labs Inc. (“Biomind Labs” or the “Company”) ( NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application.

“As we advance in the development of our proprietary line of novel pharmaceuticals, we have filed a new patent application, enabling us to continue building a robust IP strategy. Our focus on our main pillar, fast-acting psychedelics, resides on two tryptamines, N,N-Dimethyltryptamine (DMT) and 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT), two molecules that have the potential to allow us to cross the barrier of 60 minutes on treatments that require a full psychedelic experience. This aligns with our second pillar – affordability. Patients are everything for us, meaning that our novel pharmaceuticals are being developed for all patients that require an alternative medication to traditional anti-depressants, regardless of income level”, said Alejandro Antalich, CEO of Biomind Labs.

Article content

The patent application filed in the USPTO relates to Biomind Labs’ proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice.

About Biomind Labs Inc.
Biomind is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind is developing novel pharmaceutical formulations of the main natural psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind’s focus is to guarantee patients access to affordable and modern-day treatments and use cases. Biomind understands that long-lasting psychedelic effects make it difficult to create adequate clinical protocols to serve a larger number of patients, and this is the reason why Biomind specializes in fast-acting psychedelics.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Article content

Forward-looking statements in this document include, among others, statements relating to building a robust IP strategy, expectations regarding the potential of the Company’s products and methods to alleviate certain mental conditions, the business plans and growth plans of the Company, including but not limited to the development of fast relief treatments that require a full psychedelic experience at an affordable price and other statements that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not completed clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Article content

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005045/en/